https://fdawatch.net/2026/04/27/cautious-optimism-surrounding-rare-diseases-and-orphan-drugs/FDA Watch Podcasten2026-04-27T13:13:11+00:00Cautious Optimism Surrounding Rare Diseases and Orphan DrugsFDA, regulation, FDA Watch, health, healthcare, technology, art, politics, data, science, orphan drugs, rare diseases, ultra-rare diseases, Hyman Phelps McNamara, HPM, regulatory policy, real-world evidence, Geoffrey Levitt, Frank Sasinowski, argenx, patient engagement, regulatory flexibility, gene therapy, plausible mechanism framework, individualized therapieshttps://fdawatch.net/wp-content/uploads/2025/08/fdawatch_artworkupdated8.5.jpg?w=150